Telomir Pharmaceuticals (TELO) Interest Expenses (2022 - 2026)
Telomir Pharmaceuticals (TELO) posted Interest Expenses of $11.3 million for Q4 2025, up 196.71% sequentially from $3.8 million in Q2 2025, and up 1127487700.0% YoY from N/an in Q4 2024.
Telomir Pharmaceuticals (TELO) Interest Expenses (2022 - 2026) Analysis & Trends
Telomir Pharmaceuticals has reported Interest Expenses for 4 years, with the latest figure at $11.3 million in Q4 2025.
- Quarterly Interest Expenses rose 1127487700.0% year-over-year to $11.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.3 million (up 159.88% YoY) and the FY2025 annual result came in at $11.3 million, up 56.98% from the prior year.
- Interest Expenses improved to $11.3 million in Q4 2025 per TELO's latest filing, from $3.8 million in the prior quarter.
- Over five years, Interest Expenses peaked at $11.3 million in Q4 2025 and troughed at -$1.0 in Q2 2024.
- A 4-year average of $2.1 million and a median of $510067.5 in 2022 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses slumped 100.0% in 2024, then surged 1127487700.0% in 2025.
- Over 4 years, Interest Expenses stood at $262962.0 in 2022, then surged by 189.71% to $761824.0 in 2023, then tumbled by 100.0% to -$1.0 in 2024, then soared by 1127487700.0% to $11.3 million in 2025.
- According to Business Quant data, Interest Expenses over the past three periods registered $11.3 million, $3.8 million, and -$1.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 82.05 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 20.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 93.62 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -4.89 Mn |
| 10 | Telomir Pharmaceuticals | 68.14 Mn | 68.14 Mn | - | 3,028.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,028.00 |
| Jun 30, 2026 | 3,028.00 |
| Dec 31, 2025 | 11.27 Mn |
| Dec 31, 2025 | 11.27 Mn |
| Jun 30, 2025 | 3.80 Mn |
| Jun 30, 2025 | 3.80 Mn |
| Dec 31, 2024 | -1.00 |
| Dec 31, 2024 | -1.00 |
| Sep 30, 2024 | 1.00 |
| Sep 30, 2024 | 1.00 |
| Jun 30, 2024 | -1.00 |
| Jun 30, 2024 | -1.00 |
| Mar 31, 2024 | 4.34 Mn |
| Mar 31, 2024 | 4.34 Mn |
| Dec 31, 2023 | 761,824.00 |
| Dec 31, 2023 | 761,824.00 |
| Sep 30, 2023 | 757,173.00 |
| Sep 30, 2023 | 757,173.00 |
| Jun 30, 2023 | 124,052.00 |
| Jun 30, 2023 | 124,052.00 |